Mark Cuban tries to shake up biosimilar pricing with a version of J&J’s Stelara
In its latest bid to shake up the prescription drug market, the Mark Cuban Cost Plus Drug Company…
Launch prices for new drugs ‘significantly’ exceed inflation, analysis says
Amid intensifying angst over prescription drug prices, a new analysis found that the median net price for 154…
Let the rulemaking begin: Why direct-to-consumer drug ads deserve a closer look
Call it death by disclosure. After nearly 30 years in which prescription drug ads have become a fixture…
US drug pricing shake-up threatens access to medicines in Europe – POLITICO
For European drugmakers there are still many unknowns about how the MFN scheme — and overall tariffs on…